Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sonoma Pharmaceuticals (SNOA) Gross Margin (2016 - 2025)

Sonoma Pharmaceuticals has reported Gross Margin over the past 16 years, most recently at 37.94% for Q4 2025.

  • For Q4 2025, Gross Margin rose 231.0% year-over-year to 37.94%; the TTM value through Dec 2025 reached 38.16%, up 217.0%, while the annual FY2025 figure was 38.25%, 99.0% up from the prior year.
  • Gross Margin for Q4 2025 was 37.94% at Sonoma Pharmaceuticals, roughly flat from 37.83% in the prior quarter.
  • Over five years, Gross Margin peaked at 46.53% in Q4 2023 and troughed at 8.99% in Q1 2021.
  • A 5-year average of 33.42% and a median of 37.15% in 2025 define the central range for Gross Margin.
  • Biggest five-year swings in Gross Margin: crashed -4733bps in 2021 and later surged 2449bps in 2023.
  • Year by year, Gross Margin stood at 41.45% in 2021, then tumbled by -32bps to 28.23% in 2022, then surged by 65bps to 46.53% in 2023, then fell by -23bps to 35.63% in 2024, then increased by 6bps to 37.94% in 2025.
  • Business Quant data shows Gross Margin for SNOA at 37.94% in Q4 2025, 37.83% in Q3 2025, and 36.46% in Q2 2025.